The FDA launched a pilot program to retain early drug research in the US and held hearings on psychedelic medicine regulations. Meanwhile, GSK acquired a novel cancer therapy from Chimagen for up to $750 million, and Veracyte expanded its urology portfolio through a $150 million acquisition. These developments occurred alongside clinical trial failures at Sionna Therapeutics and Axoltis Pharma, as well as a $385 million settlement by Abbott Laboratories over infant formula claims.
01Policy
FDA Integrates Feedback into New Clinical Trial Pilot Program
Parallelizing trial site preparation and ethics reviews addresses regulatory lag directly, targeting the structural delay that drove domestic drug developers to license Chinese assets.
The Food and Drug Administration launched the Expedited Investigational New Drug Pilot program on September 15, 2026, opening applications to accelerate early for new medicines. The initiative forms part of Operation TrialBlazer, an effort announced by the Department of Health and Human Services in June to counter the migration of early-stage drug research to countries like China and Australia. Under the program, the agency will select eight to 10 pairings of drug sponsors and qualified research institutions to submit applications through a rolling review process. Applications remain open until October 30, 2026. Bringing a drug into clinical trials in the United States typically takes up to two years, whereas foreign jurisdictions often clear trials in a fraction of that time through streamlined reviews and financial incentives. China-run studies grew from under 1,000 annually in 2010 to more than 5,000 in 2024, outpacing the U.S. rate of about 3,500 per year. The pilot aims to eliminate regulatory bottlenecks by running trial site preparation and ethics reviews in parallel rather than in sequence, reducing the risk of clinical holds. Drug developers have signed more than 100 licensing deals with Chinese counterparts since the start of 2025 as large pharmaceutical companies seek to shore up lagging domestic pipelines.
GSK Acquires Chimagen T-Cell Engager Asset for Up to $750 Million
Engineered trispecifics that reduce the severe toxicities of existing bispecifics allow drugmakers to move T-cell engagers out of late-stage salvage use into earlier, broader oncology markets.
GSK has agreed to pay up to $750 million for a Chimagen Biosciences trispecific T-cell engager targeting multiple myeloma. The deal initiates phase 1 development for the blood cancer candidate next year. Chimagen designed the trispecific antibody to bind two tumor-associated antigens and T cells simultaneously, aiming to improve tolerability and durability compared to existing bispecific therapies. Current multiple myeloma T-cell engagers carry boxed warnings for neurologic toxicity and cytokine release syndrome and are restricted to patients who have failed at least four prior lines of therapy. GSK previously partnered with Chimagen two years ago on a $300 million upfront licensing deal for a lupus prospect.
Sionna Lays Off 46% of Staff Following Cystic Fibrosis Trial Failure
Failing to add efficacy to an incumbent drug shifts clinical risk from standalone targeted science to unproven dual-pipeline combinations to salvage valuation.
Sionna Therapeutics is laying off 46 percent of its staff following the failure of its cystic fibrosis drug candidate SION-719. The company employed 59 full-time workers at the start of the year and also lost Chief Business Officer Caroline Stark Beer in the restructuring. A prior mid-stage trial of SION-719 failed to show a statistically significant reduction in sweat chloride when added to Vertex Pharmaceuticals drug Trikafta. Sionna will now pivot its resources toward a phase 2a study combining SION-451 and SION-2222. The restructuring will cost roughly $6.4 million in the near term and leaves the biotech with $268.3 million in cash as of the end of June, extending its runway into the second half of 2029.
Axoltis Phase 2 Trial for ALS Drug Fails to Meet Primary Endpoint
Pivoting to secondary claudin-5 signals after failing the primary neurofilament light chain endpoint exposes how biotechs rely on secondary biomarker success to justify continued clinical spend.
Axoltis Pharma reported that its Phase 2 trial for experimental ALS drug NX210c missed its primary endpoint. The double-blind, randomized, multicenter study enrolled 82 patients in France who received doses of 5 mg/kg or 10 mg/kg of the synthetic peptide or a placebo three times weekly for four weeks. Patients did not show a statistically significant change from baseline in blood neurofilament light chain at six weeks. Axoltis pointed to secondary endpoints, noting a significant decrease in blood claudin-5 among patients treated with 10 mg/kg of NX210c compared to placebo recipients. The biotech plans to advance the drug to the next stages of clinical development despite the primary endpoint miss.
Abbott Agrees to Settlement Regarding US Baby Formula Plant Closure
Concentrating nationwide infant formula production in single massive facilities transforms localized quality control failures into systemic supply shocks and direct Department of Justice regulatory enforcement.
Abbott Laboratories agreed to pay $385m to resolve a Department of Justice investigation and lawsuit regarding contamination at its baby formula plants in Sturgis, Michigan, and Casa Grande, Arizona. The settlement resolves claims that the healthcare group failed to meet statutory, regulatory, and contractual requirements in producing infant formula and nutritional therapy products. Under the agreement, Abbott will pay $348.7m to the federal government and $36.3m to certain states to settle claims tied to and the Special Supplemental Nutrition Program for Women, Infants, and Children. Three former Abbott employees will receive $69m as their share of the federal recovery under the False Claims Act. Abbott maintained that the settlement does not represent a finding of fault or liability, and noted that regulators never found Cronobacter sakazakii in unopened, distributed products.
FDA Advisory Hearing Focuses on Psychedelic Provider Credentials and Access
Mandating high-credentialed monitors or full psychotherapy raises session labor costs, threatening the lean delivery models commercializing psychedelic therapies.
The convened a public hearing to examine real-world access, monitoring, and provider credentialing standards as the agency approaches potential approvals for psychedelic medicines. Companies such as Compass Pathways and Definium Therapeutics currently utilize dosing session monitors during supervised treatments rather than full psychotherapy models, a distinction that has driven progress. Industry participants debated whether the agency should mandate strict psychiatric credentials, existing nursing professionals, or rely on non-physician monitors backed by on-call physicians. Critics warned that stringent geographic and staffing requirements, such as a mandated 15-minute physician arrival window outlined in July , could restrict patient access in western states. Experts also emphasized the clinical value of integrating traditional psychotherapy into psychedelic treatment protocols despite corporate efforts to streamline delivery costs.
Veracyte Completes $150M Acquisition of Convergent Genomics
Combining urine, tissue, and blood diagnostics under one channel allows Veracyte to capture consecutive testing touchpoints throughout bladder cancer care rather than competing solely on initial diagnosis.
Veracyte acquired Convergent Genomics for $150 million in upfront cash, adding the developer's UroAmp urinary tumor DNA platform to its urology diagnostics . The deal includes up to $30 million in additional cash consideration tied to reimbursement milestones for the testing technology. Veracyte funded the initial purchase through its existing cash reserves while absorbing Convergent into its ongoing operational framework without altering its 2026 adjusted . The transaction expands Veracyte's bladder cancer offerings alongside its existing Decipher Bladder and TrueMRD tests by integrating urine-based genomic analysis with its existing tissue and blood testing channels. Convergent brings a clinical laboratory in South San Francisco and an established research footprint spanning over 30 global sites. Veracyte plans to commercialize an initial UroAmp test targeting post-induction therapy monitoring in late 2028, pending reimbursement timelines.
Heavy corporate dealmaking and regulatory adjustments contrast sharply with costly clinical trial failures and major legal settlements. It remains unclear whether new FDA incentives can effectively keep early-stage clinical research from moving overseas.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.